Previous 10 | Next 10 |
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its ...
2023-09-28 07:31:31 ET More on Immunovant, Roivant, etc. Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade) Skin In The Game: Behind Roivant's Significant Rise ...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipat...
2023-09-27 12:21:54 ET Shares of Immunovant (NASDAQ: IMVT) , an autoimmune specialist and subsidiary of Roivant Sciences (NASDAQ: ROIV) , are showing no signs of cooling off after nearly doubling in value on Tuesday. Specifically, the drugmaker's shares were up by another 5....
2023-09-27 10:29:47 ET More on Immunovant Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade) Immunovant, Inc. 2023 Q2 - Results - Earnings Call Presentation Imm...
2023-09-27 09:55:35 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ShiftPixy Inc (NASDAQ: PIXY), Galecto Inc (NASDAQ: GLTO), Cardiff Oncology Inc (NASDAQ: CRDF), American Strat...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-27 05:30:40 ET Summary Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confidence, and we expect more upside from here. IMVT-1402's proposed subcutaneous route of administration a...
2023-09-26 22:12:00 ET Roivant Sciences ( NASDAQ: ROIV ) stock price surged on Tuesday as investors cheered the latest developments with Immunovant (NASDAQ: IMVT). The shares jumped by more than 20% and retested the year-to-date high of $12.90. They have soared by more than 390% fro...
2023-09-26 17:13:07 ET More on Immunovant Seeking Alpha’s Quant Rating on Immunovant Historical earnings data for Immunovant Financial information for Immunovant Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade) Immunovant...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...